ESC Professional Premium Access

State-of-the-art lecture in lipid lowering therapy and the atheroma .

Congress Presentation

About the speaker

Professor Stephen Nicholls

Monash University, Melbourne (Australia)
51 presentations

2 more presentations in this session

Longer-term safety of alirocumab with 24,610 patient-years of placebo-controlled observation: Further insights from the ODYSSEY OUTCOMES trial

Speaker: Doctor S. Goodman (Toronto, CA)


Interrelation between baseline plaque characteristics and changes in coronary atherosclerosis with the PCSK9-inhibitor alirocumab: Insights from the PACMAN-AMI randomized trial

Speaker: Doctor K. Koskinas (Bern, CH)


Access the full session

Lipid-lowering therapy and the atheroma

Speakers: Professor S. Nicholls, Doctor S. Goodman, Doctor K. Koskinas

About the event


ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb